QURE uniQure N.V. gains 45% Jul 27, 2017

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company offers Glybera, a gene therapy product for the treatment of patients with lipoprotein lipase deficiency. It is also developing AMT-060, a gene therapy that is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-110, a gene therapy that has been completed Phase I/II clinical trial for the treatment of sanfilippo B syndrome; AAV2/glial cell line-derived neurotrophic factor, which is in Phase I clinical trial for the treatment of parkinson's disease; S100A1, a preclinical product candidate for the treatment of congestive heart failure; AMT-130 for the treatment of huntington's disease; and AAV5 for the treatment of hemophilia A. The company has collaborations with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Treeway B.V., Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. http://www.priceseries.com/trade/QURE-uniQure-NV-stock-gains-45-percent-a-Trade-Record-by-priceSeries-2017062120170727.html